This article is part of the Medical Insights vertical on Op-Med, which features study breakdowns, resources, and insights from Doximity members on popular topics in medicine. Want to submit to Medical Insights? See our submission guidelines here; note that we are especially interested in articles covering oncology, dermatology, or rheumatology.
New Study Places Lithium at Heart of Alzheimer’s, but Human Trials Remain Necessary
A 10-year investigation by Harvard Medical School, published in August in Nature, reveals that decreased endogenous lithium levels in the brain may be among the earliest molecular changes in Alzheimer’s disease (AD). The study shows that in human brain tissue, lithium is significantly reduced in the prefrontal cortex (PFC) of individuals with mild cognitive impairment (MCI) and AD, compared to cognitively normal aging. Lithium depletion appears to result in part from sequestration by amyloid-β plaques. This finding has sparked renewed interest in lithium as a possible therapeutic avenue, although the translational path remains uncharted.
From Trace Element to Central Player
In their study, investigators examined postmortem human brain tissue spanning the spectrum from cognitively normal aging to MCI and advanced AD. They discovered that lithium was the only metal consistently depleted across the disease continuum. Importantly, the degree of depletion correlated with disease severity. Unlike nutritional deficiencies of other trace elements, lithium loss appeared to result from sequestration. Amyloid-β plaques bound lithium directly, reducing its bioavailability and possibly accelerating the neurodegenerative cascade.
Experimental Models Reveal Causal Links
To test causality, the team used mouse models in which dietary lithium was reduced by about 50%. The consequences were compelling. These animals developed increased amyloid-β and phosphorylated tau deposition, activated microglia, synaptic and myelin loss, and accelerated cognitive decline. Conversely, administration of lithium orotate, a formulation engineered to avoid strong plaque binding, prevented and even reversed these pathological features. Treated animals regained memory performance on behavioral tasks, and researchers observed no major organ toxicity during the study period. These findings suggest that lithium homeostasis is not merely correlative but may be mechanistically central to neurodegeneration.
Context: What Do We Already Know About Lithium in AD?
The new results do not emerge in isolation. Lithium has long been of interest in neurodegeneration because of its known ability to inhibit glycogen synthase kinase-3β (GSK-3β), an enzyme implicated in tau phosphorylation. Prior clinical studies tested lithium carbonate in patients with mild cognitive impairment or early AD and reported slowed cognitive decline. Additionally, a retrospective cohort study reported an association between lithium use and a decreased risk of developing dementia.
Parallel to clinical trials, epidemiological studies have suggested that populations with higher trace lithium levels in drinking water have lower rates of dementia. While these observations are intriguing, they are not definitive, given the difficulty of controlling environmental and lifestyle confounders. Still, taken together, they have kept the lithium hypothesis alive in neurology and psychiatry.
Promise and Peril of Lithium Orotate
The present findings revive the field by introducing a new formulation, lithium orotate, that appears able to bypass plaque sequestration and deliver lithium to vulnerable brain regions more efficiently than standard lithium salts. If these preclinical results translate to humans, they could mark a paradigm shift in Alzheimer’s research. However, several challenges loom large. Lithium orotate is not FDA-approved for any indication, and its pharmacokinetics and long-term safety profile in humans remain poorly characterized. The therapeutic window for lithium is notoriously narrow, and systemic toxicity remains a significant concern.
Cautious Optimism
The Harvard study underscores a broader conceptual shift in AD research. Rather than focusing exclusively on removing amyloid or tau aggregates, investigators are considering the maintenance of broader neuronal homeostasis, including trace element balance, as a therapeutic strategy. Yet the translation from bench to bedside is fraught with risk. Animal models, though indispensable, remain imperfect reflections of human disease. Moreover, any clinical trial will need to rigorously balance efficacy with safety, particularly for older patients who may already have renal or thyroid vulnerabilities.
For now, the study’s implications are twofold. Scientifically, it opens a fresh and biologically plausible avenue for understanding AD. Clinically, it offers a note of cautious optimism, but not a license for off-label self-medication. The road ahead requires carefully designed trials, transparent safety monitoring, and continued exploration of how such a common trace element might reshape our approach to one of the most devastating neurodegenerative disorders.
Dr. Jones is a neurologist passionate about preserving brain health and exploring everyday strategies to prevent cognitive decline and dementia.
Image by Anton Vierietin / Shutterstock
